Discretionary transaction by Baker Bros. Advisors Lp of tradable shares of Kala Pharmaceuticals subject to Rule 16b-3
KALA Stock | USD 6.46 0.09 1.37% |
About 68% of Kala Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Kala Pharmaceuticals stock suggests that many investors are alarmed at this time. The current market sentiment, together with Kala Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kala Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kala |
Filed transaction by Kala Pharmaceuticals 10 Percent Owner. Discretionary transaction in accordance with Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Kala Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Kala Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Kala Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kala Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kala Pharmaceuticals Fundamental Analysis
We analyze Kala Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Kala Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Kala Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kala Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kala Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kala Pharmaceuticals Related Equities
DERM | Journey Medical | 5.43 | ||||
ORGO | Organogenesis Holdings | 5.14 | ||||
BFRI | Biofrontera | 3.48 | ||||
LFCR | Lifecore Biomedical | 1.53 | ||||
DVAX | Dynavax Technologies | 0.08 | ||||
NBIX | Neurocrine Biosciences | 0.12 | ||||
ITCI | Intracellular | 2.18 | ||||
ALKS | Alkermes Plc | 2.27 | ||||
SHPH | Shuttle Pharmaceuticals | 3.85 | ||||
AKAN | Akanda Corp | 4.24 | ||||
CPHI | China Pharma | 4.76 |
Complementary Tools for Kala Stock analysis
When running Kala Pharmaceuticals' price analysis, check to measure Kala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kala Pharmaceuticals is operating at the current time. Most of Kala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |